Dyax Corp. is a biopharmaceutical company that is dedicated to the development of innovative treatments for rare diseases. The company's flagship product, Shir, has been approved by the FDA for the treatment of angioedema caused by hereditary deficiency of C1 esterase inhibitor (HAE). Uses: Shir, also known by its generic name ecallantide, is a plasma kallikrein inhibitor that works by blocking the activation of the plasma kallikrein system. This system is known to play a role in the development of angioedema, which is a type of allergic reaction that causes swelling of the skin, mucous membranes, and internal organs. In clinical trials, Shir has been shown to significantly reduce the frequency and severity of HAE attacks. It can be administered via subcutaneous injection and is typically used as a preventative measure for patients with HAE. Dosage: The recommended dosage of Shir for the prevention of HAE attacks is 30 mg administered subcutaneously twice a week. However, the dosage may be adjusted based on the patient's individual response to treatment. Side Effects: Like all medications, Shir can cause side effects in some patients. The most common side effects reported in clinical trials include injection site reactions, such as redness, swelling, and itching. Other side effects may include headache, nausea, and diarrhea. In rare cases, Shir may cause serious allergic reactions, including anaphylaxis. Patients should seek immediate medical attention if they experience symptoms of an allergic reaction, such as difficulty breathing, swelling of the face and throat, and chest pain. Interactions: Shir has not been studied in combination with other medications and there are no known drug interactions. However, patients should always inform their healthcare provider of all medications they are currently taking, including prescription, over-the-counter, and herbal supplements. Generic: Shir is also known by its generic name, ecallantide. Generic medications are typically priced lower than name-brand medications, making them a more affordable option for many patients. Demographic: Shir is primarily used to treat patients with hereditary deficiency of C1 esterase inhibitor (HAE), a rare genetic disease that affects roughly 1 in 10,000 to 1 in 50,000 individuals worldwide. HAE is most commonly diagnosed in individuals between the ages of 10 and 30, and it affects both males and females equally. In conclusion, Shir is a plasma kallikrein inhibitor developed by Dyax Corp. that is used to prevent attacks of angioedema caused by HAE. The medication is injected subcutaneously and has been shown to significantly reduce the frequency and severity of attacks. While side effects are possible, the medication is generally well-tolerated by patients. Patients with HAE should discuss the use of Shir with their healthcare provider to determine if it is an appropriate treatment option for them.